51. Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study
- Author
-
Jean Carlo Gorinchteyn, Roberto Dias de Oliveira, Rodrigo Fabiano do Carmo Said, Regiane Cardoso de Paula, Julio Croda, Tatiana Lang D'Agostini, Mario Sergio Scaramuzzini Torres, Murilo Dorion Neto, Wade L. Schulz, Patricia Vieira da Silva, Jason R. Andrews, Wildo Navegantes de Araújo, Edlaine Faria de Moura Villela, Albert I. Ko, Maria Almiron, Otavio T. Ranzani, Matthew D. Hitchings, Derek A. T. Cummings, Olivia Ferreira Pereira de Paula, and Silvano Barbosa de Oliveira
- Subjects
Pediatrics ,medicine.medical_specialty ,education.field_of_study ,Transmission (medicine) ,business.industry ,Population ,Psychological intervention ,Context (language use) ,Disease ,Vaccination ,Regimen ,Pandemic ,medicine ,education ,business - Abstract
Background Mass vaccination is being used in response to coronavirus disease (COVID-19) epidemics, including those driven by emerging variants of concern. We evaluated the effectiveness of the inactivated whole-virus vaccine, CoronaVac, against symptomatic COVID-19 in the elderly population of Sao Paulo State, Brazil during widespread circulation of the P.1 variant. Methods We conducted a test-negative, case-control study of adults ≥70 years of age from Sao Paulo State from January 17 to April 29, 2021, during which vaccination with a two-dose regimen of CoronaVac was implemented. We identified RT-PCR-confirmed COVID-19 cases as well as controls who had a symptomatic illness with a negative RT-PCR test from national surveillance and state vaccination databases. Controls were pair-matched to cases by age category, sex, self-report race, municipality, prior COVID-19 status, and date of RT-PCR testing. We estimated vaccine effectiveness, adjusted for age and comorbidities, using conditional logistic regression. Findings We selected 7,950 matched pairs with a mean age of 76 years from 26,433 COVID-19 cases and 17,622 test-negative controls. Adjusted vaccine effectiveness was 18.2% (95% CI, 0.0 to 33.2) and 41.6% (95% CI, 26.9 to 53.3) in the period 0-13 and ≥14 days, respectively, after the 2nd dose. Administration of a single vaccine dose was not associated with reduced odds of COVID-19. Vaccine effectiveness ≥14 days after the 2nd dose declined with increasing age and was 61.8% (95% CI 34.8 to 77.7), 48.9% (95% CI 23.3 to 66.0) and 28.0% (95% CI 0.6 to 47.9) among individuals 70-74, 75-79 and ≥80 years of age, respectively (pinteraction = 0.05). Interpretation CoronaVac was 42% effective in the real-world setting of extensive P.1 transmission, but significant protection was not observed until completion of the two-dose regimen and vaccine effectiveness declined with increasing age. These findings underscore the need to maintain non-pharmaceutical interventions when mass vaccination with CoronaVac is used as part of an epidemic response. Funding Pan American Health Organization. Research in context Evidence before this study We searched Pubmed for articles published from inception of the pandemic until May 10, 2021, with no language restrictions, using the search terms “vaccine”, “COVID-19”, “SARS-CoV-2”, “elderly”, “age”, “older”. Randomised controlled trials (RCTs) have yielded varying estimates (51-84%) for the effectiveness of the inactivated whole-virus vaccine, CoronaVac, against symptomatic COVID-19. Current evidence is lacking on whether CoronaVac or other COVID-19 vaccines are effective against disease caused by the SARS-CoV-2 variant of concern, P.1, or in a setting of extensive P.1 circulation. No studies have reported the real-world effectiveness of CoronaVac and other inactivated vaccines among elderly individuals, a population that was underrepresented in RCTs of these vaccines. Added value of this study In a population-based matched test-negative case-control study, we found that a two-dose regimen of CoronaVac had an effectiveness of 42% in preventing symptomatic COVID-19 among adults ≥70 years of age during an epidemic associated with widespread P.1 variant transmission. Significant protection was not observed until the period ≥14 days after administration of the second dose. We observed a significant decline in vaccine effectiveness with increasing age in the elderly population. Implications of all the available evidence In the setting of extensive P.1 transmission, the effectiveness of CoronaVac in adults ≥70 years of age was similar to that observed in RCTs conducted in younger populations prior to the emergence of P.1. These findings provide supportive evidence for the use of this vaccine in countries that are experiencing P.1-associated epidemics. However, significant protection was not detected until after administration of the second dose, indicating that vaccination in countries where CoronaVac supplies are constrained may need to prioritize completion of the two dose regimen among the highest risk populations. The delay in achieving vaccine-mediated protection also underscores the need to initiate and maintain non-pharmaceutical interventions when mass vaccination with CoronaVac is used in a response to an epidemic. National immunisation programs should optimise the vaccination of the very elderly (≥80 years), accounting for specific vaccines or vaccination schemes.
- Published
- 2021
- Full Text
- View/download PDF